| Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study YP Mossé, MS Lim, SD Voss, K Wilner, K Ruffner, J Laliberte, D Rolland, ... The lancet oncology 14 (6), 472-480, 2013 | 790 | 2013 |
| Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study YP Mossé, SD Voss, MS Lim, D Rolland, CG Minard, E Fox, P Adamson, ... Journal of Clinical Oncology, JCO. 2017.73. 4830, 2017 | 386 | 2017 |
| Activating FGFR2–RAS–BRAF mutations in ameloblastoma NA Brown, D Rolland, JB McHugh, HC Weigelin, L Zhao, MS Lim, ... Clinical Cancer Research, 2014 | 284 | 2014 |
| Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia MJ Kiel, T Velusamy, D Rolland, AA Sahasrabuddhe, F Chung, NG Bailey, ... Blood 124 (9), 1460-1472, 2014 | 260 | 2014 |
| Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome MJ Kiel, AA Sahasrabuddhe, DCM Rolland, T Velusamy, F Chung, ... Nature communications 6 (1), 8470, 2015 | 212 | 2015 |
| MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes E Lages, A Guttin, M El Atifi, C Ramus, H Ipas, I Dupré, D Rolland, ... PLoS One 6 (5), e20600, 2011 | 189 | 2011 |
| Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? A Traverse-Glehen, L Baseggio, E Callet-Bauchu, D Morel, S Gazzo, ... Blood 111 (4), 2253-2260, 2008 | 172 | 2008 |
| A metabolic function of FGFR3-TACC3 gene fusions in cancer V Frattini, SM Pagnotta, JJ Fan, MV Russo, SB Lee, L Garofano, J Zhang, ... Nature 553 (7687), 222-227, 2018 | 164 | 2018 |
| High-frequency targetable EGFR mutations in sinonasal squamous cell carcinomas arising from inverted sinonasal papilloma AM Udager, DCM Rolland, JB McHugh, BL Betz, C Murga-Zamalloa, ... Cancer research 75 (13), 2600-2606, 2015 | 144 | 2015 |
| A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders T Velusamy, MJ Kiel, AA Sahasrabuddhe, D Rolland, CA Dixon, ... Blood 124 (25), 3768-3771, 2014 | 101 | 2014 |
| Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK–mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma SRP McDonnell, SR Hwang, D Rolland, C Murga-Zamalloa, V Basrur, ... Blood 122 (6), 958-968, 2013 | 70 | 2013 |
| Colony-stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-cell Lymphoma Viability C Murga-Zamalloa, DCM Rolland, A Polk, A Wolfe, H Dewar, ... Clinical Cancer Research, clincanres. 1486.2019, 2019 | 49 | 2019 |
| Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas DCM Rolland, V Basrur, YK Jeon, C McNeil-Schwalm, D Fermin, ... Proceedings of the National Academy of Sciences 114 (25), 6581-6586, 2017 | 42 | 2017 |
| Global Phosphoproteomic Profiling Reveals Distinct Signatures in B-Cell Non-Hodgkin Lymphomas D Rolland, V Basrur, K Conlon, T Wolfe, D Fermin, AI Nesvizhskii, MS Lim, ... The American journal of pathology 184 (5), 1331-1342, 2014 | 35 | 2014 |
| Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin D Rolland, M Raharijaona, A Barbarat, R Houlgatte, C Thieblemont Anticancer research 30 (10), 3951-3957, 2010 | 34 | 2010 |
| FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells R Saffie, N Zhou, D Rolland, Ö Önder, V Basrur, S Campbell, KE Wellen, ... Cancer research 80 (12), 2498-2511, 2020 | 25 | 2020 |
| NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma CA Murga-Zamalloa, V Mendoza-Reinoso, AA Sahasrabuddhe, ... Oncogene 36 (15), 2085-2094, 2017 | 24 | 2017 |
| Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma D Rolland, V Camara-Clayette, A Barbarat, G Salles, B Coiffier, V Ribrag, ... Cancer chemotherapy and pharmacology 61 (5), 855-863, 2008 | 23 | 2008 |
| Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial D Rolland, V Ribrag, C Haioun, H Ghesquieres, F Jardin, R Bouabdallah, ... Cancer chemotherapy and pharmacology 65 (4), 781-790, 2010 | 20 | 2010 |
| A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates … A Awasthi, DCM Rolland, J Ayello, C van de Ven, V Basrur, K Conlon, ... Oncotarget 8 (69), 113895, 2017 | 17 | 2017 |
